An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with
moderate hepatic impairment and healthy controls. The trial consisted of a screening visit, a
treatment phase and a follow-up visit. All subjects were to be treated with study medication
for 8 consecutive days. Blood and urine were collected for the PK analysis, and safety
assessments were performed.